Policy and Advocacy Updates

• ISPE Funded Manuscripts
  • There were 14 proposals submitted for the 2023 Call for Funded Manuscript Program. A total of 6 manuscript writing teams were awarded funds to develop their manuscript. In total, ISPE provided $49,900 in support of the Funded Manuscript Program. Congratulations to the writing teams!

     

    Lead Author	Manuscript Title
    Amie Goodin	Curriculum Assessment of Pharmacoepidemiology Training Programs
    Edward Lai	Bridging Linguistic Gaps in Training the New Generation of Pharmacoepidemiologist in Non-native English-speaking Countries: Examples from East and Southeast Asian Countries
    Oluwadamilola Onasanya	Framework to Optimize Oncology Line of Therapy Enumeration in Real-World Databases: Evidence from a Scoping Review of Published Algorithms and Expert Panel Consensus/Recommendations
    Elizabeth Russell	Equity in Pharmacoepidemiology: A Framework for Ensuring Representative Study Populations and Improving Understanding of Benefit-Risk
    Maribel Salas	Real-World Evidence (RWE) Databases for Pharmacoepidemiological Research in Africa
    Mollie Wood	Estimands for designing medications in pregnancy and lactation (MiPAL) studies to answer clinical and regulatory research questions

• Manuscripts Considered for ISPE Endorsement
  • Since August 2023, 14 manuscripts have been submitted to the PPC for review in consideration of ISPE endorsement. Eight have received ISPE endorsement, and the remainder are in various stages of review.

• Review of ISPE Policies
  • 13 existing ISPE policies were reviewed this year as part of the annual policy review process. Recommendations are made to renew for another 3-year term, revise if the policy content is out of date but the topic remains relevant to ISPE or retire if the content is no longer relevant. Recommendations will be presented to the Board at the annual meeting.

• Solicitation of Emerging Topics & Advocacy Issues
  • Member solicitation for emerging topics and advocacy issues was open from May 1-19, 2024. Upon review and evaluation, those warranting further action will be presented to the Board for consideration.